66342-1-Ig

antibody from Proteintech Group

Targeting: PLOD2 LH2

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

66342-1-Ig

Provider

Proteintech Group

Product name

PLOD2 antibody

Antibody type

Monoclonal

Description

KD/KO validated PLOD2 antibody (Cat. #66342-1-Ig) is a mouse monoclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, WB,ELISA.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Isotype

IgA

Antibody clone number

1H9E1

Vial size

20ul, 150ul

References

Submitted references

Hypoxia-Driven Immune Escape in Clear Cell Renal Cell Carcinoma: A Prognostic Model and Dual-Functional Biomarker PLOD2 for Immunotherapy Stratification.

Xiao F, Guan Y, Song H, Xiang W
Journal of Cancer 2026;17(2):217-234

---

Matrix stiffness promotes corneal fibrosis through the YAP/TAZ-β-catenin mechanotransduction pathway: Proteomic and functional validation.

Li K, Fu H, Miao L, Lu Y, He C, Liu Y, Hu Z, Xie B, Lv X, Lu F, Lin M, Hu L
Acta biomaterialia 2026 Jun;216:215-233

---

Prognostic biomarker and clinical significance of PLOD gene family in clear cell renal cell carcinoma.

Shang X, Liu L, Yang Z, Yan M, Ren R, Guo K, Wang J, Zhang W, Chang J, Li J, Cao J, Li G, Gao L
Frontiers in oncology 2025;15:1613540

---

CKAP4 and PLOD2 as novel prognostic biomarkers in hepatocellular carcinoma: a proteomics-driven risk stratification model.

Lu Q, Cao Z, Xiong Y, Huang J, Zeng H, Chen Z, Shu Y, Tan Y, Long X, Liu X, Shu H
Frontiers in cell and developmental biology 2025;13:1577161

---

FAP(+) fibroblasts orchestrate tumor microenvironment remodeling in renal cell carcinoma with tumor thrombus.

Ma J, Huang Y, Chen J, Li Y, Yao R, Li X, Liang Q, Chen X, Peng C, Liu K, Zhai Y, Zhang X, Ma X, Wang X, Huang Q, He F
Nature communications 2025 Oct 23;16(1):9387

---

Hypoxia-induced circPLOD2a/b promotes the aggressiveness of glioblastoma by suppressing XIRP1 through binding to HuR.

Yu A, Wang Y, Duan C, Qin J, Liao M, Zhu H, Lei J, Liu J, Yang Z, Yu L, Gui H, Xin J, Tao W, Bao W, Dong Z
Communications biology 2025 Jan 17;8(1):71

---

Targeting RORγ inhibits the growth and metastasis of hepatocellular carcinoma.

Liu Q, Wang J, Sun H, Zhang Z, Wang H, Ma S, Zhang C, Wang Q, Cai G, Zheng J, Nie Y, Liu P, Wang J
Molecular therapy : the journal of the American Society of Gene Therapy 2024 Mar 6;32(3):749-765

---

Systematic characterization of the expression, prognosis and immune characteristics of PLOD family genes in breast cancer.

Wang DD, Li L, Fu YQ, Yang SJ, Chen X, Hou JC, Zhang Q, Tian XX, Tang JH, Zhang J, Zhang HD
Aging 2024 Jul 26;16(14):11434-11445

---

Hypoxia-induced PLOD2 promotes clear cell renal cell carcinoma progression via modulating EGFR-dependent AKT pathway activation.

Liu T, Xiang W, Chen Z, Wang G, Cao R, Zhou F, Meng Z, Luo Y, Chen L
Cell death & disease 2023 Nov 27;14(11):774

---

Loss of RhoE Function in Dermatofibroma Promotes Disorganized Dermal Fibroblast Extracellular Matrix and Increased Integrin Activation.

Endzhievskaya S, Hsu CK, Yang HS, Huang HY, Lin YC, Hong YK, Lee JYW, Onoufriadis A, Takeichi T, Yu-Yun Lee J, Shaw TJ, McGrath JA, Parsons M
The Journal of investigative dermatology 2023 Aug;143(8):1487-1497.e9

---

Identification and Validation of a Nine-Gene Amino Acid Metabolism-Related Risk Signature in HCC.

Zhao Y, Zhang J, Wang S, Jiang Q, Xu K
Frontiers in cell and developmental biology 2021;9:731790